Plan ahead

Plan ahead of these events, and schedule time with us!

We can help you:


Understand the landscape in seconds for the targeted therapy of your choice.

Book a demo

To book a live demo to show you how this works specifically to your questions.

Events Beacon will be attending

 2nd Annual TIGIT Therapies Summit 2021

December 7-9, 2021, Digital Event

The  2nd Annual TIGIT Therapies Summit remains the only dedicated forum gathering biopharma drug developers to discuss this next-generation checkpoint inhibitor to advance clinical progress and deliver to those patients most in need.

This event will allow you to address the key challenges associated with TIGIT therapy development and propel TIGIT to clinical use.

Register Here

DDR, ATR & PARP Inhibitors Summit 2022

January 25-27, 2022 Boston, MA

The 5th Annual PARP, ATR & DDR Inhibitors Summit is the one-of-a-kind industry-focused summit dedicated to bringing new and novel next-generation DDR therapeutics to the clinic and finding optimal treatment combinations to expand application in multiple cancer indications.

This is the key in-person biopharma conference for any research team developing inhibitors of specific DDR targets, in either monotherapy or in combination, to treat predictable, identifiable, DDR-defective cancer indications

Register Here

LAG-3 Targeted Drug Development Summit 2022

January 25-27, 2022 | Digital Event

With the recent clinical validation by BMS, LAG-3 combinations are spearheading the next wave of immune checkpoint inhibitors. As such, there has been an explosion of interest and high-scale investment into this exciting space.

Arriving at a critical point for LAG-3 development, the first ever LAG-3 Targeted Drug Development Summit is the definitive industry-led event focused on propelling this next generation inhibitor to clinical use.

Here’s what you can look forward to:

  • Get clinical updates on current bispecific antibody approaches from Laura Codari Deak (Roche Innovation Center), Michelle Morrow (F-Star Biotechnology) and Paul Moore (Macrogenics)
  • Take a look at the potential of LAG-3 in haematological cancers with Segundo Rodriguez (Universidad de Oviedo)
  • Explore the mechanism of action and understand how LAG-3 mediates its inhibitory function with Creg Workman (University of Pittsburgh)
  • Understand how LAG-3 acts in non-oncological conditions with our interactive online workshop with Jon Piganelli (University of Pittsburgh)
Register Here

Conference Tracker

Upcoming events

Due to the impacts of COVID-19, we will be monitoring the activities of key conferences, to find out more about how we monitor this, please view our conference tracker.

Conference Tracker